(Washington, D.C.): The U.S. Court of Appeals for the Fifth Circuit has granted a motion to stay the Food and Drug Administration’s (FDA) 2023 Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, which established mail-order access to the abortion drug beginning under the Biden Administration.
This stay was granted upon appeal by the plaintiffs, including the State of Louisiana, after the U.S. District Court the Western District of Louisiana granted standing but denied the stay, allowing the FDA six months to complete its safety review of the drug. The Fifth Circuit’s order is effective immediately, pending appeal to the Supreme Court.
John Mize, CEO of Americans United for Life (AUL), stated, “In a monumental win for women across the nation, the Fifth Circuit has halted dangerous, mail-order abortion, allowing those harmed to finally experience the justice they long deserve. Americans United for Life carries confident hope this will be upheld upon likely appeal. One battle at a time, the Pro-Life Movement continues to see hard-fought victories that daily bring our nation closer to a restored culture of life.”
Sarah Zagorski, Senior Director of Public Relations and Communications for AUL, emphasized, “In the name of access, mail-order abortion was exploited by abusers and coercive partners to target women across the nation. Today, we can celebrate that the online abortion industry’s lucrative business is immediately halted, pending appeal, and women in America can rest easier tonight.”
For more information or to arrange an interview with AUL, contact Gavin Oxley at [email protected] or 202-987-3321.
Since 1971, Americans United for Life (AUL) has advanced the human right to life in culture, law, and policy by equipping advocates and lawmakers with the facts and strategies that change hearts and minds and protect human life. The first national pro-life organization in the country, AUL is a nonprofit, public-interest law and policy organization with a four-star rating from Charity Navigator.
